Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan

AIMS: To examine the expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in breast lesions, and to correlate it with the expression of hyaluronan (HA). Methods and results: CD 44 expression was studied in 75 breast tissue samples, consisting of benign, premalignant and malignant breast lesions, using immunohistochemistry. CD 44 s, but not CD 44 v 3 or CD 44 v 6, was found in the stromal cells, and it was similar in benign and malignant tumours. In benign lesions CD 4 v 6 was detected in 20-30% of the ductal epithelial cells, while C 44 v 3 and CD 44 s were not expressed. CD 44 s, CD 44 v 3 and CD 44 v 6 were all up-regulated in the in situ carcinomas and invasive carcinomas. The level of CD 44 expression in carcinoma cells did not correlate with the type or differentiation of the tumours. CD 44 and HA expression levels were not closely linked in the benign or malignant breast lesions, because HA was overexpressed later in breast cancer progression than CD 44. However, in breast carcinomas CD 44 and HA positivity was often found in the same areas of the sections, and the dual staining confirmed actual colocalization of CD 44 s and HA in the same cells. Conclusions: CD 44 s, CD 44 v 3 and CD 44 v 6 are up-regulated earlier than HA in breast carcinoma progression, and in later stages they often colocalize with cell surface HA.     

CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression

Background: Currently, it is difficult to predict the prognosis of patients exhibiting stage II or stage III colorectal cancer (CRC) and to identify those patients most likely to benefit from aggressive treatment. The current study was performed to examine the clinicopathological significance of CD44 and CD44v6 protein expression in these patients. Study design: We retrospectively investigated 187 consecutive patients who underwent surgery with curative intent for stage II to III CRC from 2007 to 2013 in the Beijing Civil Aviation Hospital. CD44 and CD44v6 protein expression levels were determined using immunohistochemistry and compared to the clinicopathological data. Results: Using immunohistochemical detection, CD44 expression was observed in 108 (57.75%) of the CRC patients; and its detection was significantly associated with greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological tumor-lymph node-metastasis (TNM) stage. CD44v6 expression was observed in 135 (72.19%) of the CRC patients; and its expression was significantly associated with a poorly differentiated histology, greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological TNM stage. Expression of CD44v6 was higher than that of CD44 in stage II and stage III sporadic CRC. Conclusion: CD44v6 is a more useful marker for predicting a poor prognosis in stage II and stage III sporadic CRC as compared to CD44.     

肿瘤干细胞相关标记物CD44及CD24在乳腺癌中的表达及其意义

目的探讨肿瘤干细胞相关标记物CD44及CD24在乳腺癌组织中的表达特点、CD44+/CD24-细胞与HER-2、ER、PR、CK5/6表达的相互关系及其与临床病理因素的关系。方法采用免疫组化SP单染及双染法检测42例乳腺导管原位癌及126例乳腺浸润性导管癌组织中CD44及CD24的表达情况,检测126例乳腺浸润性导管癌组织中HER-2、ER、PR、CK5/6表达状况以进行免疫分型。结果 (1)CD44阳性定位于癌细胞膜。在浸润癌中阳性率为56.3%,在导管原位癌中阳性率为85.7%。两者差异有显著性意义(P<0.05)。在不同分化程度的乳腺浸润性癌中,CD44阳性率分别为69.2%、58.1%及44.7%,差异有显著性意义(P<0.05)。(2)CD24阳性表达于非癌性乳腺组织中小管的腔缘;在癌组织中除腔缘阳性外,可出现膜质阳性。在浸润癌中阳性率为32.5%,在导管原位癌中阳性率为64.3%。两者差异有显著性意义(P<0.05)。(3)126例浸润性导管癌中CD44+/CD24-者65例,占51.6%;CD44+/CD24-阳性细胞在Luminal A型为47.5%、Luminal B型为42.9%、HER-...     

胃良恶性病变组织中CD24和CD44v6的表达及其意义

目的： 研究胃良恶性病变组织中癌干细胞标记物CD24、CD44v6的表达并探讨其临床病理意义。方法: 49例胃癌、20例癌旁组织、36例淋巴结转移灶及80例不同类型胃良性病例（浅表性胃炎10例，萎缩性胃炎15例，胃溃疡20例，胃息肉20例，胃腺瘤15例）标本常规制作石蜡包埋切片，CD24和CD44v6染色方法为EnVision免疫组化法。结果: 胃癌病例CD24和CD44v6表达阳性率明显高于癌旁组织和不同类型胃良性病变（P＜0.05或P＜0.01），且阳性表达的良性病例胃黏膜上皮均呈中至重度不典型增生；转移灶CD24和CD44v6表达与相应原发灶呈现高度一致性（P>0.05）；组织学分级Ⅱ级、无淋巴结转移及无远处器官转移胃癌病例CD24和CD44v6表达阳性率明显低于组织学分级Ⅲ或Ⅳ级、淋巴结转移及远处器官转移病例（P＜0.05）。此外，浸润深度T₁-T₂及淋巴结N1站转移病例CD24表达阳性率明显低于浸润深度T₃-T₄和淋巴结N₂、N₃站转移病例（P＜0.05）。结论: CD24和CD44v6表达可能是反映胃癌发生、进展、生物学行为和预后的重要癌干细胞标记物，检测胃良性病例CD24和CD44v6表达水平对预防和早期发现胃癌可能有一定的临床价值。     

CD44 and its partners in metastasis

The establishment of metastasis requires that tumor cells acquire new adhesion and migration properties to emigrate from primary sites and colonize distant organs. CD44 is a cell membrane protein often overexpressed on tumor cells and, being both a cell–cell and cell–extracellular matrix adhesion protein, is well positioned to contribute to this process. Furthermore the interaction of CD44 with other cellular proteins involved in motogenesis and proteolysis is a determinant factor in cell migration and invasion. This review summarizes current knowledge on the role of CD44 in metastasis, as well as the challenges on understanding how this process operates. This revised version was published online in July 2006 with corrections to the Cover Date.     

非小细胞肺癌患者CD44及其变异体V6的测定

目的：探讨测定粘附分子CD44及其变异体V₆在非小细胞肺癌（non-smallcelllungcarcinoma, NSCLC）中的意义。方法：采用酶联免疫吸附试验检测血清中可溶性CD44S（sCD44S）和可溶性CD44V₆（sCD44V₆）含量;流式细胞术测定细胞表面CD44S、CD44V₆的表达。结果：NSCLC患者血清CD44S、CD44V₆水平明显高于肺良性疾病（P<0.05, P<0.01）。原发肺鳞癌（SCC）和腺癌（ADC）细胞的CD44S表达率明显高于对照组（P<0.01）;3组的CD44V₆表达率均低,差异无显著。NSCLC原发癌细胞表面CD44S、CD44V₆表达与其血清的可溶性含量之间均无相关性。结论：提示血清CD44S、CD44V₆水平可作为鉴别NSCLC和肺良性疾病的辅助指标。     

CD44 expression is up-regulated in the deep zone of osteoarthritic cartilage from human femoral heads

 

Aims:

The objective of this study was to detail the topographical and zonal distribution of the cell adhesion molecule CD44 in normal and osteoarthritic cartilage.  

Methods and results:

Immunohistochemistry utilizing well characterized anti-CD44 antibodies (clones A3D8, Bric 235, 2C5) was performed on cryostat and paraffin sections of human articular cartilage from macroscopically normal ( n  = 18) and osteoarthritic ( n  = 11) femoral heads. Samples for cryostat sections were obtained from 12 topographically different sites. Sections were divided into zones (superficial, middle, deep) and the CD44 staining scored. Chondrocytes in normal articular cartilage and cartilage from osteoarthritic femoral heads stained positive for CD44 in both cryostat and paraffin sections. Normal cartilage showed a significant decrease in CD44 staining in the deep zone as compared to the superficial zone ( P  < 0.05). However, cryostat sections of residual cartilage from osteoarthritic femoral heads showed increased CD44 staining in the deep zone as compared to normal articular cartilage. The CD44 staining showed no topographical variation in either the normal cartilage or the osteoarthritic residual cartilage.  

Conclusions:

CD44 expression displays a distinct zonal variation in normal articular cartilage which is lost in osteoarthritic cartilage due to an up-regulated expression in the deep zone. CD44 expression does not exhibit topographical variation.     

CD44 expression in soft tissue sarcomas

Recent studies have shown that expression of alternatively splicing variants of CD44 is correlated with prognosis for several kinds of malignant tumors. However, little is known about the expression of CD44 standard and variant isoforms in soft tissue sarcomas. In this study 47 cases of soft tissue sarcoma [18 malignant fibrous histiocytomas (MFHs), 13 synovial sarcomas (SSs), 7 malignant schwannomas (MSs), and 9 liposarcomas (LSs)] were examined immunohistochemically. The monoclonal antibodies to the standard form of CD44 (CD44H) and variant exons of CD44v3, 4, 5, 6, 7, 9, and v10 were used. We analyzed the membranous expression pattern of CD44H and CD44 variant exons and assessed the relation between expression of CD44s and metastasis-free survival rates (MFSR) of patients with soft tissue sarcoma. A few sarcomas expressed CD44v3 (2/47) and v7 (2/47), but none of the sarcomas expressed CD44v10. CD44v4 (5/47), v5 (4/47), v6 (10/47), and v9 (9/47) are relatively common types of variant isoforms in soft tissue sarcomas. Expression of CD44v6 is more frequently detected in high-grade than in low-grade tumors. CD44v6 or CD44v9 expression was correlated with metastasis-free survival of patients with soft tissue sarcomas. Received: 22 Juni 1999 / Accepted: 19 November 1999     

血清sCD44s及sCD44v6变化与乳腺癌的初步研究

目的:测定血清中sCD44s和sCD44v6含量并探讨其在乳腺癌中的临床意义。方法:用酶联免疫吸附试验(ELISA)检测38例乳腺癌患者及15例乳腺良性疾病患者和40例正常人血清中可溶性CD44s(sCD44s)和可溶性CD44v6(sCD44v6)的水平。结果:乳腺癌患者血清sCD44s和sCD44v6水平明显高于正常人和乳腺良性疾病患者(P＜0.01)。Ⅲ、Ⅳ期患者血清sCD44s和sCD44v6明显高于Ⅰ、Ⅱ期(P＜0.05);乳腺癌手术后1周sCD44v6明显低于手术前(P＜0.05),手术后2周sCD44v6更加明显(P＜0.01);手术后2周sCD44s明显低于手术前(P＜0.05)。结论:血清sCD44s和sCD44v6水平可作为诊断、治疗乳腺癌的辅助指标;乳腺癌血清中sCD44s和sCD44v6升高及降低与肿瘤负荷有关。     

CD44 expression in plexiform lesions of idiopathic pulmonary arterial hypertension

Plexiform lesions in pulmonary arteries are a characteristic histological feature for idiopathic pulmonary arterial hypertension (IPAH). The pathogenesis of the plexiform lesion is not fully understood, although it may be related to endothelial cell dysfunction and local inflammation. CD44 is a cell adhesion molecule and it is also involved in angiogenesis, endothelial cell proliferation and migration. The expression of CD44 was examined in lung plexiform lesions obtained from patients with IPAH (IPAH group, n= 7) and pulmonary arterial hypertension associated with atrial septal defect (ASD-PAH group, n= 4). Expression of CD44 was detected in 49 out of 52 plexiform lesions (93%) from all patients in the IPAH group, whereas 31 plexiform lesions obtained from the ASD-PAH group lacked CD44 positivity by immunohistochemistry. In the IPAH group, CD44 was localized in the endothelial cells of microvessels within plexiform lesions and activated T cells in and around the lesions. Furthermore, T cell infiltration and endothelial cell proliferation activity were prominent in the plexiform lesions of the IPAH group, compared to those of the ASD-PAH group. These findings suggest that CD44 and activated T cell infiltration play an important role in the development of plexiform lesions particularly in IPAH.     

Expression of CD44 in Canine Mammary Tumours

CD44 is an important adhesion molecule for hyaluronan, a major component of the extracellular matrix (ECM). In human breast cancer, the interaction of tumour cells with the ECM via CD44 is favoured as a major candidate for tumour progression and metastasis. The present study was designed to investigate immunohistochemically the expression of the standard form of CD44 in normal, hyperplastic and neoplastic canine mammary tissue. CD44 was expressed in normal and hyperplastic mammary tissue predominantly by ductal and alveolar epithelial cells and to a minor extent by myoepithelial cells. Stromal cells and blood vessels displayed low to moderate CD44 expression. In simple and complex adenomas and benign mixed tumours there was significant up-regulation of CD44 expression in alveolar epithelial cells compared with adjacent non-neoplastic mammary tissue. Peripheral epithelial cells of simple and complex adenomas, benign mixed tumours and complex carcinomas expressed significantly more CD44 compared with adjacent non-neoplastic mammary tissue. Peripheral epithelial cells of simple adenomas revealed a significantly higher CD44 expression compared with simple carcinomas. A statistical trend to greater CD44 expression was found in peripheral epithelial cells of complex adenomas, benign mixed tumours and complex carcinomas compared with simple carcinomas. Up-regulation of CD44 therefore appears to be associated with benign or relatively benign biological behaviour of canine mammary tumours.     

非小细胞肺癌中CD44v6的表达

目的　探讨CD4 4v6表达与非小细胞肺癌临床病理特征之间的关系。方法　采用免疫组化S P法检测 132例非小细胞肺癌、6 6例淋巴结转移癌和 115例正常肺组织CD4 4v6表达的情况。结果　非小细胞肺癌CD4 4v6阳性表达率为4 8 4 8% ,高于正常肺组织 17 39%的阳性表达率。CD4 4v6阳性表达与淋巴结转移状况、TNM分期、肿瘤大小和组织学类型有相关性。非小细胞肺癌淋巴结转移组、TNMⅢ期患者、直径 >3cm的肿瘤和鳞癌CD4 4v6阳性表达率分别高于无淋巴结转移组、TNMⅠ期和Ⅱ期患者、直径≤ 3cm的肿瘤和腺癌。淋巴结转移癌CD4 4v6阳性表达率高于肺原发癌。CD4 4v6阳性表达与患者的性别、年龄和组织学分级无相关性。结论　CD4 4v6阳性表达预示非小细胞肺癌具有较强的侵袭和转移能力 ,可作为一项预测非小细胞肺癌转移潜能生物学指标。     

CD44和CD44v6基因在胃腺癌组织中的表达及其意义

目的： 研究胃腺癌组织中ＣＤ４４ 的表达及其与淋巴结转移和预后的关系。方法： 应用免疫组化方法, 对１０５ 例胃腺癌组织中ＣＤ４４ 的表达进行了观察, 并对其中６２ 例患者做了随访。结果： ＣＤ４４ 和ＣＤ４４ｖ６ 基因的表达率分别为５４－３ ％ 和４８－６ ％ 。ＣＤ４４ｖ６ 在胃腺癌组织中的表达与癌细胞的分化、浸润深度, 以及临床分期和预后有关（Ｐ＜ ０－０５）, 而ＣＤ４４ 的表达则与上述临床病理指标无关。另外, 抗ＣＤ４４ 和抗ＣＤ４４ｖ６ 抗体的阳性反应, 与癌细胞的淋巴结转移有关（ＣＤ４４ｖ６, Ｐ＜ ０－０１ ; ＣＤ４４ , Ｐ＜ ０－０５） 。结论： ＣＤ４４ 的表达可用于胃癌患者的病情监测, 其中ＣＤ４４ｖ６ 有望作为判断预后的一个指标。     

Evaluation of osteopontin and CD44v6 expression in odontogenic cystic lesions by immunohistochemistry

Odontogenic cysts are common lesions with different biological behavior. Odontogenic keratocysts (OKCs) and calcifying odontogenic cysts (COCs) with ameloblastoma-like epithelium are more aggressive than dentigerous cysts (DCs) and radicular cysts (RCs). Therefore, they were included in the list of odontogenic tumors by WHO. Osteopontin (OPN) is a calcium-binding glycoprotein present in many normal tissues. It plays a role in the migration and invasion of transformed epithelial cells. Binding of OPN to its receptor CD44v6 can enhance cell motility and migration. The purpose of this study was to compare the expression of these markers between odontogenic cysts of varying biological behavior. We examined OPN and CD44v6 expression in tissue sections of 14OKCs, 14COCs, 14RCs and 14DCs by immunohistochemistry. OPN and CD44v6 immunostaining was observed in all lining epithelial cells of the studied lesions with different degrees. The highest level of OPN and CD44v6 expression was found in OKCs, followed by COCs, RCs and DCs. Comparison of both markers among four groups revealed significant differences (P<0.001). Our findings suggest that higher level of OPN and CD44v6 expression in epithelial cells of some lesions such as OKC and COC can explain the local aggressive behavior of them.     

甲状腺髓样癌中CD133和CD44的表达及意义

目的 探讨肿瘤干细胞(cancer stem cells,CSC)标志物CD133及CD44在甲状腺髓样癌(medullary thyroid cancer,MTC)组织中的表达及临床病理意义.方法 采用免疫组化SP法检测51例MTC组织中CD133和CD44的表达.结果 (1)CD133蛋白在MTC伴有包膜浸润组的阳性率(76.2％,16/21)明显高于无包膜浸润组(43.3％,13/30);CD133蛋白在MTC病灶直径≥1 cm组的阳性率(64.4％,29/45)显著高于病灶直径＜1 cm组(0,0/6),差异均有统计学意义(P均＜0.05).(2)CD44蛋白在MTC伴有包膜浸润组的阳性率(66.7％,14/21)明显高于无包膜浸润组(20％,6/30),差异有统计学意义(P＜0.01).(3) MTC中CD133和CD44蛋白的表达与患者年龄、性别、是否散发、甲状腺受累范围、淋巴结转移、远处脏器转移、TNM分期均无关(P＞0.05).(4)CD133与CD44共表达与MTC包膜浸润密切相关(P＜0.01).结论 MTC中存在CSC,其与肿瘤的浸润生长及恶性增殖相关,可考虑将CD133及CD44作为MTC临床评价肿瘤生物学行为的指标.二者可能存在互相调节的机制,共表达在MTC的恶性进展中发挥作用.